Abstract
Tricuspid regurgitation (TR) is the most common pathology for the tricuspid valve. Moderate to severe TR is associated with morbidity and adverse outcomes. The concept that TR resolves on its own if the underlying disease is successfully treated has proven to be false. Only a few patients with significant TR are deemed suitable for surgery. Given the late presentation of patients with high perioperative risks and substantial perioperative mortality, the development of transcatheter therapies and the experience gained with transcatheter aortic valve implantation operations have turned attention towards treating this challenging group of patients. In this article, we review the treatment options and highlight the role of transcatheter valve therapies in patients with severe TR.
Reference52 articles.
1. Fender EA, Zack CJ, Nishimura RA. Isolated tricuspid regurgitation: outcomes and therapeutic interventions. Heart 2018;104:798-806.
2. Taramasso M, Gavazzoni M, Pozzoli A, et al. Outcomes of TTVI in patients with pacemaker or defibrillator leads: data from the trivalve registry. JACC 2020;13:554-64.
3. Prihadi EA. Tricuspid valve regurgitation: no longer the ‘forgotten valve. J Cardiol Pract 2018;16.
4. Kirklin JK, Blackstone EH. Kirklin/Barratt-Boyes Cardiac Surgery. Amsterdam: Elsevier Health Sciences; 2012.
5. Izumi C, Miyake M, Takahashi S, et al. Progression of isolated tricuspid regurgitation late after mitral valve surgery for rheumatic mitral valve disease. J Heart Valve Dis 2022;11:353-6.